Vital Transformation is a small, unique consultancy focused on addressing the challenges of today’s modern healthcare system. We partner with your organisation to help you find answers to hard to solve problems.
Contact us to learn how Vital Transformation can help your organisation.
LATEST RESEARCH
LATEST COMMUNICATIONS
Our Communication Services
In this special 2025 U.S. Policy Highlights edition of the Vital Health Podcast, we look back at our most important discussions on the Inflation Reduction Act (IRA) and its ripple effects across drug development, Medicare, and patient access. Over the past year, the biopharma industry and the broader healthcare system have undergone a period of rapid change as new rules surrounding drug pricing reshape how therapies are developed, financed, and delivered. In a landscape where policies are still being interpreted and adjusted, and where the long-term impact on innovation and access is far from certain, this episode serves as a year-end guide to what has changed and how to think about the road ahead.
Find all our communication projects on Better Science, Better Health
MORE RESEARCH
Real world big data for clinical research and drug development
30th December, 2017
The objective of this paper is to identify the extent to which real world data (RWD) is being utilized, or could be utilized, at scale in drug development. Through screening peer-reviewed literature, we have cited specific examples where RWD can be used for biomarker discovery or validation, gaining a new understanding of a disease or disease associations, discovering new markers for patient stratification and targeted therapies, new markers for identifying persons with a disease, and pharmacovigilance.
Medicines Adaptive Pathways to Patients (MAPPs): A Story of International Collaboration Leading to Implementation
21st October, 2015
After nearly a decade of discussion, analysis, and development, the Medicines Adaptive Pathways to Patients (MAPPs) initiative is
beginning to see acceptance from regulators, industry, patients, and payers, with the first live pilot project initiated under the
guidance of the European Medicines Agency in 2014.
Report: The challenges and changes needed to reengineer medicines development in the UK
9th March, 2015
A new report from the ABPI and Vermilion Life Sciences examines the challenges and changes needed for the UK to lead reengineering medicines development, and proposes a new methodology to achieve this.
VITAL HEALTH PODCASTS
Our podcast series is also available via your favourite channels!
 |
 |
|---|---|
 |
 |
NEWSLETTER
Register now to receive all the latest updates from Vital Transformation including our research, podcasts and more…
VT on X
Claims that the IRA wouldn’t affect innovation overlooked how early-stage investors really make decisions. Our research shows the pipeline for senior-focused therapies is already narrowing.
— VitalTransformation (@VitalTransform) April 18, 2025
Read the full breakdown: https://t.co/4EzJGdMcU4@weworkforhealth #IRA #DrugPricing
The IRA’s 9-year cap for small molecules and 13-year cap for biologics rerouted investment away from the pills seniors rely on. We sat down with @steveusdin1 to unpack how this shift skews R&D incentives and future therapies.
— VitalTransformation (@VitalTransform) April 27, 2025
Listen here: https://t.co/FCjKFdIhsU@weworkforhealth pic.twitter.com/phoDI4ZrhK
Our clients include many of the world’s leading health care organisations.
